摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

地昔卡因 | 24358-84-7

中文名称
地昔卡因
中文别名
——
英文名称
(+)-Mepivacaine
英文别名
Dexivacaine;(2S)-N-(2,6-dimethylphenyl)-1-methylpiperidine-2-carboxamide
地昔卡因化学式
CAS
24358-84-7
化学式
C15H22N2O
mdl
——
分子量
246.352
InChiKey
INWLQCZOYSRPNW-ZDUSSCGKSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    148-150 °C
  • 沸点:
    383.1±42.0 °C(Predicted)
  • 密度:
    1.077±0.06 g/cm3(Predicted)
  • 溶解度:
    可溶于氯仿(少许)、甲醇(少许)

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    18
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.53
  • 拓扑面积:
    32.3
  • 氢给体数:
    1
  • 氢受体数:
    2

ADMET

毒理性
  • 在妊娠和哺乳期间的影响
哺乳期使用总结:目前没有关于哺乳期间使用美普卡因的信息。基于其他局部麻醉药进入母乳的排泄量较低,哺乳期间单次使用美普卡因不太可能对哺乳婴儿产生不利影响。然而,可能会优先选择其他药物,特别是在哺乳新生儿或早产儿时。 在分娩期间给母亲用作局部麻醉的美普卡因有报道称会干扰一些婴儿的初始哺乳行为,但对产后前5天的体重增长没有影响。尽管没有针对美普卡因进行很好的研究,但看起来在良好的哺乳支持下,硬脊膜外麻醉药(无论是否加用芬太尼或其衍生物)对哺乳成功几乎没有或没有不利影响。分娩疼痛药物可能会延迟哺乳的开始。需要更多的研究来阐明美普卡因在分娩期间对哺乳结果的影响。 对哺乳婴儿的影响:截至修订日期,没有找到相关的已发布信息。 对哺乳和母乳的影响:在一项比较正常分娩期间硬脊膜外注射美普卡因、布比卡因和利多卡因用于镇痛的研究中,三组母乳喂养婴儿在分娩后前5天的体重变化没有差异。所有组的总体体重增长均在正常范围内。 在6名母亲在分娩前1小时内接受会阴阻滞美普卡因的婴儿中,有4名开始哺乳行为的时间较长,最初哺乳的次数少于10名在分娩期间未接受麻醉的母亲所生的婴儿。这些差异的长期后果没有报告。 一项全国性的调查比较了从晚期妊娠到产后12个月期间接受和未接受分娩疼痛药物的母亲及其婴儿的哺乳II期(lactogenesis II)的时间。药物类别包括仅硬脊膜外或脊髓麻醉、硬脊膜外或脊髓麻醉加另一种药物,以及其他疼痛药物。接受任何类别药物的母亲与未接受分娩疼痛药物的母亲相比,哺乳II期延迟(>72小时)的风险大约是两倍。
◉ Summary of Use during Lactation:No information is available on the use of mepivacaine during breastfeeding. Based on the low excretion of other local anesthetics into breastmilk, a single dose of mepivacaine during breastfeeding is unlikely to adversely affect the breastfed infant. However, an alternate drug may be preferred, especially while nursing a newborn or preterm infant. Mepivacaine given during labor as a local anesthetic to the mother has been reported to interfere with initial nursing behavior of some infants, but not weight gain during the first 5 days postpartum. Although not well studied specifically with mepivacaine, it appears that with good breastfeeding support, epidural local anesthetics with or without fentanyl or one of its derivatives has little or no adverse effect on breastfeeding success. Labor pain medication may delay the onset of lactation. More study is required to clarify the effect of mepivacaine during labor on breastfeeding outcome. ◉ Effects in Breastfed Infants:Relevant published information was not found as of the revision date. ◉ Effects on Lactation and Breastmilk:In a study that compared extradural administration of mepivacaine, bupivacaine and lidocaine for analgesia during normal childbirth, no differences were found in weight changes over the first 5 days after delivery among the breastfed infants of the 3 groups. Overall weight gain was within normal limits for all groups. Of 6 infants whose mothers received a pudendal block with mepivacaine within the hour before delivery, 4 took longer to begin nursing behavior and nursed less initially than 10 infants whose mothers received no anesthesia during labor. The long-term consequences of these differences were not reported. A national survey of women and their infants from late pregnancy through 12 months postpartum compared the time of lactogenesis II in mothers who did and did not receive pain medication during labor. Categories of medication were spinal or epidural only, spinal or epidural plus another medication, and other pain medication only. Women who received medications from any of the categories had about twice the risk of having delayed lactogenesis II (>72 hours) compared to women who received no labor pain medication.
来源:Drugs and Lactation Database (LactMed)

SDS

SDS:8fc2b8bd95175fd564f5856d7e2a54f1
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    地昔卡因N,N-二异丙基乙胺 作用下, 以 乙腈 为溶剂, 反应 72.0h, 生成
    参考文献:
    名称:
    一种季铵盐类化合物及其用途
    摘要:
    本发明属于化学医药领域,具体涉及一种季铵盐类化合物及其用途。本发明提供了一类新的季铵盐化合物,该化合物兼具长效局部麻醉作用和选择性局部麻醉作用,具有起效快、局部麻醉作用时间长、局部麻醉选择性好、神经损伤更小、安全性高的优点。
    公开号:
    CN115385848A
  • 作为产物:
    描述:
    L-哌啶-2-甲酸盐酸potassium carbonate 作用下, 以 N,N-二甲基甲酰胺甲苯 为溶剂, 生成 地昔卡因
    参考文献:
    名称:
    (S)-2-哌可酸的便捷且高度对映选择性合成:有效获取卡因麻醉剂
    摘要:
    摘要 已经从 Oppolzer 的 sultam ( 1 ) 和N- (二苯基亚甲基) 甘氨酸乙酯 ( 2 ) 作为容易获得的起始材料实现了 ( S )-2-哌啶酸 ( 5 )的新型和对映选择性合成。手性甘氨酸中间体 ( 3 ) 与 1,4-二溴丁烷高度立体选择性烷基化,一步得到 (S)-2-哌啶酸 ( 5 )的关键骨架,用于制备局部麻醉剂甲哌卡因、罗哌卡因和布比卡因。
    DOI:
    10.1080/00397911.2021.1961155
点击查看最新优质反应信息

文献信息

  • ASYMMETRIC BIFUNCTIONAL SILYL MONOMERS AND PARTICLES THEREOF AS PRODRUGS AND DELIVERY VEHICLES FOR PHARMACEUTICAL, CHEMICAL AND BIOLOGICAL AGENTS
    申请人:The University of North Carolina at Chapel Hill
    公开号:US20170021030A1
    公开(公告)日:2017-01-26
    Asymmetric bifunctional silyl (ABS) monomers comprising covalently linked pharmaceutical, chemical and biological agents are described. These agents can also be covalently bound via the silyl group to delivery vehicles for delivering the agents to desired targets or areas. Also described are delivery vehicles which contain ABS monomers comprising covalently linked agents and to vehicles that are covalently linked to the ABS monomers. The silyl modifications described herein can modify properties of the agents and vehicles, thereby providing desired solubility, stability, hydrophobicity and targeting.
    描述了包含共价连接的药物、化学和生物试剂的不对称双功能硅基(ABS)单体。这些试剂也可以通过硅基团共价结合到传递载体上,以将试剂传递到所需的靶标或区域。还描述了包含共价连接试剂的ABS单体的传递载体,以及与ABS单体共价连接的载体。本文描述的硅基修饰可以修改试剂和载体的性质,从而提供所需的溶解性、稳定性、疏水性和靶向性。
  • PHOSPHONIUM ION CHANNEL BLOCKERS AND METHODS FOR USE
    申请人:Nocion Therapeutics, Inc.
    公开号:US20210128589A1
    公开(公告)日:2021-05-06
    The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof: The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, itch, and neurogenic inflammation.
    本发明提供了式(I)的化合物,或其药用可接受的盐: 本发明的化合物、组合物、方法和试剂盒可用于治疗疼痛、瘙痒和神经性炎症。
  • [EN] HETEROCYCLIC COMPOUNDS AND THEIR USE AS RETINOID-RELATED ORPHAN RECEPTOR (ROR) GAMMA-T INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ET LEUR UTILISATION EN TANT QU'INHIBITEURS GAMMA-T DU RÉCEPTEUR ORPHELIN APPARENTÉ AUX RÉCEPTEURS DES RÉTINOÏDES (ROR) )
    申请人:TAKEDA PHARMACEUTICAL
    公开号:WO2016002968A1
    公开(公告)日:2016-01-07
    Provided are heterocyclic compounds having a RORγt inhibitory action represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    提供的是具有RORγt抑制作用的杂环化合物,其由公式(I)表示:其中每个符号如说明书中定义,或其盐。
  • CONJUGATE-BASED ANTIFUNGAL AND ANTIBACTERIAL PRODRUGS
    申请人:Bapat Abhijit S.
    公开号:US20140364595A1
    公开(公告)日:2014-12-11
    The invention provides conjugate-based antifungal or antibacterial prodrugs formed by coupling at least one anti-fungal agent or antibacterial agent with at least one linker and/or carrier. The prodrugs are of formula: (i) (AFA) m -X-(L) n ; (ii) [(AFA) m′ -X] p -L; (iii) AFA-[X-(L) n′ ] q ; or (iv) (AFA) m″ -X, wherein: AFA is an antifungal agent or an antibacterial agent; L is a carrier; X is a linker; m ranges from 1 to 10; n ranges from 2 to 10; m′ is 1 to 10; p is 1 to 10; n′ is 1 to 10; and q is 1 to 10, provided that q′ and n are not both 1; and m″ is 1 to 10. The invention also provides nanoparticles comprising the conjugate-based prodrugs. Additionally, the invention also provides non-conjugated antifungal and antibacterial agents in the form of nanoparticles.
    该发明提供了由至少一种抗真菌剂或抗菌剂与至少一种连接剂和/或载体偶联形成的基于共轭的抗真菌或抗菌前药。这些前药的公式为:(i) (AFA) m -X-(L) n ; (ii) [(AFA) m′ -X] p -L; (iii) AFA-[X-(L) n′ ] q ; 或 (iv) (AFA) m″ -X,其中:AFA是抗真菌剂或抗菌剂;L是载体;X是连接剂;m范围从1到10;n范围从2到10;m′为1到10;p为1到10;n′为1到10;q为1到10,前提是q'和n不同时为1;m″为1到10。该发明还提供了包含基于共轭的前药的纳米粒子。此外,该发明还提供了以纳米粒子形式的非共轭抗真菌和抗菌剂。
  • Base-stabilized polyorthoester formulations
    申请人:Shah T. Devang
    公开号:US20070264338A1
    公开(公告)日:2007-11-15
    A stabilized semi-solid delivery vehicle contains a polyorthoester and an excipient, and a pharmaceutical composition contains an active agent, optionally a stabilizing agent, and the delivery vehicle. The pharmaceutical composition may be a topical, syringable, or injectable formulation; and is suitable for local delivery of the active agent. Methods of treatment are also disclosed.
    一种稳定的半固态给药载体包含聚正交酯和辅料,以及一种药物组合物包含活性药剂,可选地包含稳定剂和给药载体。该药物组合物可以是局部、可注射或可注射的配方;适用于活性药剂的局部给药。还公开了治疗方法。
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸 麦撒奎 鹅膏氨酸 鹅膏氨酸 鸦胆子酸A甲酯 鸦胆子酸A 鸟氨酸缩合物